-
in limited clinical trials, metformin has been shown to have anti-cancer activity. The objective of this study was to investigate whether patients taking metformin had better disease-specific survival compared to non-consumers.
-
Most physicians who travel will encounter one or more emergencies during air travel. This paper reviews the experience of a medical communication center that serves five domestic and international airlines over a 34-month period.
-
Statin therapy has multiple beneficial effects on coronary plaque, including prevention of plaque progression and reduction in thrombotic events. It is not clear if the beneficial effect on clinical events is due to reduction in lipid content of plaque.
-
N-3 polyunsaturated fatty acids (n-3 FA) from fish have been reputed to prevent the development of cardiovascular disease (CVD) and have demonstrated some benefits in secondary prevention studies. Thus, this community-based investigator group in Italy conducted a double-blind, placebo-controlled trial of subjects with multiple risk factors for CVD (at least four, or one if diabetic) or evidence of atherosclerotic vascular disease, but without myocardial infarction (MI).
-
-
Many laboratories have changed their practice to perform some procedures without stopping warfarin anticoagulation, but trial evidence supporting this practice has been lacking. In this paper, investigators from 17 centers in Canada and one in Brazil report the results of a trial comparing continued warfarin with heparin bridging in high-risk patients undergoing device procedures.
-
Cardiovascular disease (CVD) risk calculators are frequently used by clinicians to guide patient management. Unfortunately, there are more than 100 risk calculators and smaller studies have shown insistencies between them.
-
NSAIDs and cardiovascular risk; new antithrombotic guidelines; warfarin during surgery; Pfizer selling Viagra online; azithromycin and cardiovascular risk; and FDA actions.
-
Computed tomography (CT) has evolved significantly in recent years, and is now able to accurately assess coronary arteries for the presence of atherosclerosis in carefully selected patients.
-
The FDA has approved apixaban the long-awaited third novel oral anticoagulant (NOAC) for the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (AF).